Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

17-06-2017 | EULAR 2017 | Video

EULAR 2017 highlights: Joachim Sieper

This activity is financially supported by Novartis Pharma AG

Related content

26-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

Further evidence for the benefits of ixekizumab in ankylosing spondylitis

21-02-2019 | Psoriatic arthritis | Feature | Article

The role of JAK inhibitors in the treatment of PsA

25-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Positive secukinumab results for axial manifestations in PsA

20-08-2018 | Psoriatic arthritis | Feature | Article

At a glance: Data supporting the approval of ixekizumab for PsA
Image Credits